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submissions. BCVA (Best Corrected Visual Acuity) scores were available for limited 
number of East Asian patients (N= 35) from a phase III, 12-month, randomized, 
double-masked, multicenter, active-controlled study (RADIANCE). To populate a 
transition probability matrix with 8 health states based on BCVA scores, a statisti-
cal model was proposed to simulate a larger hypothetical patient cohort. A mixed-
effect model was fitted on the observed BCVA scores with baseline BCVA score as 
covariate, patients as random effect and an autoregressive AR(1) error correlation 
structure amongst the repeated observations. This model was used to simulate a 
patient cohort of 35,000. Transition probabilities were estimated using traditional 
division by row sum method. Several simulations were run to confirm consistency 
of results. Results: From baseline to month 3, percentage of patients with BCVA 
≥ 20 letters gain was 22.45% in observed data vs 22.49% in simulated data, and 
percentage of patients with BCVA ≥ 20 letters loss was 0.008% in observed data 
vs 0.009% in simulated data. BCVA change from baseline to month 3 in simulated 
data (mean= 13.3, SD= 8.3) was verified with that of the observed data (mean= 13.3, 
SD= 8.8). ConClusions: Transition probability estimation by simulation from a 
fitted statistical model can overcome the challenges posed by small patient cohorts 
and multiple state transitions.
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objeCtives: In cost-effectiveness analysis (CEA), mean survival difference (QALY-
adjusted) over a lifetime horizon is required. Parametric models are necessary to 
extrapolate survival outcomes beyond the Randomized Controlled Trial (RCT) period. 
However, mean survival is very sensitive to the assumed model and different mean 
survival times may result from models fitting similarly well to the RCT data. We 
investigate the idea that other sources of information, external to the trial data, 
could be used to inform model choice and estimation. Methods: We explored 
various survival models and we show how external information can be used to 
put constraints on spline-based survival models. We illustrate with a Technology 
Appraisal (TA) of head and neck cancer where RCT evidence had 5 year follow up. 
A US cancer database (SEER), general population data and expert opinion were 
used to impose constraints on overall survival, conditional survival, and hazard 
ratio. RCT and external data were fitted simultaneously within a Bayesian frame-
work. Results: Standard survival time distributions were insufficiently flexible 
to simultaneously fit both the RCT data and general population constraints. Spline 
models were sufficiently flexible, although there were difficulties choosing initial 
values. A good fit to all sources of internal and external evidence was achieved 
within one integrated model using splines on the log hazard. Cetuximab in addi-
tion to radiotherapy improves the expected survival by 4.7 months [95% CrL: 0.4; 
9.1] compared to radiotherapy alone. ConClusions: The method enabled us to 
estimate models consistent with all evidence. Clinical knowledge is essential to 
guide the interpretation of the external data sources. The method could be used 
to analyze other RCTs on other cancers and with other treatments. Other flexible 
models than splines could be investigated.
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objeCtives: Health technology assessment of treatments often requires estimates 
of their survival curves. Individual patient data (IPD) are often unavailable and the 
survival curves are usually calculated by fitting a nonlinear least squares (NLS) 
model directly to Kaplan Meier plots provided in the published literature. This 
method does not account for the uncertainty associated with the Kaplan Meier 
curve and can lead to biased estimates. Although the IPD are often missing, the 
Kaplan Meier curve itself can be digitised and used to approximate what the origi-
nal IPD could have been. Methods: We simulated trial IPD data from different 
survival distributions in order to assess the accuracy of the IPD reconstruction 
methods. The assessment of accuracy is made at multiple stages and ultimately 
the effects on the incremental cost effectiveness ratio (ICER) estimates are com-
pared. To do so, a simple cost-effectiveness model was developed, assuming two 
health states (alive and dead), and assigning costs (£1,000 per month plus drug 
costs) and a utility score (0.70) to generate ICERs. Two additional methods to curve 
fitting are compared against the NLS approach – those suggested by Guyot (G), and 
by Hoyle & Henley (HH). Results: We find that the methods differ in accuracy at 
each of the following two stages; (a) model selection via the AIC and secondly (b) 
survival model parameter estimation. When an underlying Weibull function was 
assumed, the ‘true’ ICER should be £28,924, compared against £31,182 £33,449 and 
£31,650 for the NLS, HH and G methods respectively. When an underlying loglogistic 
function was assumed, the NLS, HH and GG methods produced ICERs of £26,507, 
£25,559 and £25,857, compared to a ‘true’ ICER of £25,779. ConClusions: These 
findings suggest that inherent biases may be apparent in each of the approaches, 
and these may manifest themselves differently, depending upon the ‘true’ shape 
of the underlying data.
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be viewed as biases or an expression of true preferences is a matter for further 
discussion.
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objeCtives: The first infliximab biosimilars reached the EU in September 2013, 
representing the first biosimilar monoclonal antibodies (mAbs) to obtain EMA 
approval. Although commercialization in the major European markets will only 
start in February 2015, payers in Nordic and Eastern European countries have already 
faced the dilemma of striking the balance between potential savings accrued from 
use of less expensive infliximab biosimilars and demands for robust proof of clinical 
efficacy and safety. This work identifies payers’ evidence expectations, their reli-
ance on regulators’ decisions and how potential savings can influence access and 
recommendations to target patient populations. Methods: Exploratory qualita-
tive primary research with payers (N= 12) from France, Italy, Spain, UK, Germany 
and Netherlands. Collection of data about the current and future attitudes towards 
biosimilar health technology assessments at the national and, if applicable, local 
levels will be conducted, as well as perceived price and access trade-offs. Results: 
(1) Payers will mainly defer to the EMA the decision on acceptability of biosimilar 
indication extrapolation (indications where biosimilars do not have direct clinical 
trial data); (2) It is understood that mAb biosimilar clinical development is more 
onerous and costly than small molecule generics, thus payers do not expect the 
same magnitude of discounts offered vs. originator; (3) Although eager to obtain 
savings from broad patient populations, payers will not implement pharmacy-level 
substitution or enforce biosimilar use in originator-experienced patients; (4) Use in 
naïve patients will be recommended in most markets. ConClusions: Across the 
EU5, payers acknowledge physicians’ concerns over long term safety and efficacy 
of biosimilars. Nonetheless, they will rely on the regulators evaluations and expert 
panels to justify implementing recommendations, and in some markets, restrict 
formularies based exclusively on cost. Moreover, they have conservative discount 
expectations at launch, with the long-term aim of incentivizing further competition 
from other biosimilar manufacturers.
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objeCtives: Patient-level simulation models provide increased flexibility to over-
come the limitations of cohort-based approaches in health-economic analysis. 
However, computational requirements of reaching convergence is a notorious 
barrier. The objective was to assess the impact of using quasi-monte carlo simu-
lation (QMCS) and variance reduction techniques (VRTs) on computational require-
ments. Methods: A recently published discrete event simulation model assessing 
the cost-effectiveness of an adjunctive antipsychotic treatment for depression was 
used. The following VRTs were implemented: antithetic variables, common random 
numbers (CRN) and the combination (Anti_CRN). In addition, QMCS was conducted 
using the Sobol low discrepancy sequence. The minimal number of patients required 
to reach equal precision as the reference situation of 1,000,000 simple monte carlo 
simulations (MCS) was recorded. Precision was defined by the standard error (SE) 
of the incremental net monetary benefit (INMB) at a willingness to pay of € 20,000 
per quality adjusted life year gained. VRT simulations were replicated 100 times. 
INMB estimates were compared with the reference situation using mean squared 
error (MSE), mean absolute error (MAE) and percentage of under- and overesti-
mations. Results: Reference INMB (SE) was € 1,413 (76). The average number of 
patients required to reach reference precision were 929,628, 35,692, 41,683 and 
36,803 for antithetic variables, CRN, Anti_CRN and Sobol respectively. This implied 
a computation time reduction ranging between 7% and 96% compared to simple 
MCS. MSE was 346,036, 16,314, 155,950 and 7,475 respectively. MAE was 588, 105, 
387 and 86 respectively. Antithetic variables and Anti_CRN structurally underes-
timated INMB (99% and 100%). CRN marginally overestimated INMB in 76 replica-
tions. ConClusions: QMCS and VRT reduce computational requirements in terms 
of simulated patients and computational time up to 96%, enhancing the practical 
feasibility of patient-level simulation models. This particularly applies to Sobol and 
CRN. Antithetic variables should be used with caution and its structural bias war-
rants further research.
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objeCtives: Markov model is one of the most used decision analytic models in 
health care. Transitions between health states in a Markov model is driven by tran-
sition probability matrix. When the number of patients and observed transitions 
are limited, transition probability estimation becomes challenging. The objective 
of this exercise is to demonstrate how transition probabilities can be estimated by 
simulating data from a statistical model fitted to patient-level data. Methods: 
An economic model for ranibizumab in mCNV secondary to pathological myopia 
(submitted to NICE in June 2013) was adapted for forthcoming Asian reimbursement 
